Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05635643 · ClinicalTrials.gov registry record · Phase 1

Study of CHS-114 in Participants With Advanced Solid Tumors

A Phase 1 study of Advanced Solid Tumor and Head and Neck Squamous Cell Carcinoma, sponsored by Coherus Oncology.

Recruiting
Registry status
Phase 1
Development phase
87
Enrollment target
16
Study locations

NCT05635643 is a Phase 1 study of Advanced Solid Tumor and Head and Neck Squamous Cell Carcinoma that is actively recruiting participants, run by Coherus Oncology. The registered enrollment target is 87 participants, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (55% lower). The trial reports 16 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05635643, a Phase 1 study of Advanced Solid Tumor and Head and Neck Squamous Cell Carcinoma, is actively recruiting participants, sponsored by Coherus Oncology.

RECRUITING
Registry status
Phase 1
Development phase
87 participants
Enrollment target
16
Study locations

Study Summary

This is a Phase 1, open-label, first-in-human, dose-escalation and expansion study of CHS-114, a monoclonal antibody that targets CCR8, as a monotherapy in patients with solid tumors.

Conditions Studied

Advanced Solid Tumor Head and Neck Squamous Cell Carcinoma

Interventions

  • DRUG CHS-114
  • DRUG toripalimab

Study Locations (16)

California

  • Hoag Memorial Hospital - Newport Beach
  • FOMAT Medical Research - Oxnard
  • Stanford Cancer Center - Palo Alto

Michigan

  • University of Michigan - Ann Arbor
  • Barbara Ann Karmanos Cancer Institute - Karmanos Cancer Center - Detroit

Florida

  • SCRI Lake Nona DDU (FL Cancer Specialists) - Orlando

Georgia

  • Emory Winship Cancer Institute - Atlanta

Illinois

  • Hope & Healing Cancer Services - Hinsdale

Kentucky

  • University of Louisville - Louisville

Maryland

  • University of Maryland Greenebaum Comprehensive Cancer Center - Baltimore

Missouri

  • Washington University - St Louis

Trial Details

FieldValue
Enrollment Target 87 participants
Start Date 2022-12-15
Est. Completion 2027-01-01
Phase Phase 1

Sponsor

Coherus Oncology

15 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05635643

The ClinicalTrials.gov registry entry for NCT05635643 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 87 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (55% lower). The listed sponsor is Coherus Oncology, which has 15 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Advanced Solid Tumor appearing as the primary indexed condition, and to 2 interventions - of which CHS-114 is the first listed.

NCT05635643 reports 16 study locations spanning 13 distinct geographic areas - top geographies include California, Michigan, Florida.

Frequently Asked Questions

What is clinical trial NCT05635643 about?

NCT05635643 is a clinical study titled "Study of CHS-114 in Participants With Advanced Solid Tumors". This is a Phase 1, open-label, first-in-human, dose-escalation and expansion study of CHS-114, a monoclonal antibody that targets CCR8, as a monotherapy in patients with solid tumors.

What is the current status of trial NCT05635643?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 87 participants. The study started on 2022-12-15. Estimated completion is 2027-01-01.

What conditions does trial NCT05635643 study?

This clinical trial studies the following conditions: Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma.

What interventions are being tested in trial NCT05635643?

The interventions under investigation include: CHS-114 (DRUG), toripalimab (DRUG).

Who is sponsoring clinical trial NCT05635643?

This trial is sponsored by Coherus Oncology, which has 15 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05635643 being conducted?

This trial has 16 study locations across California, Florida, Georgia, Illinois, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumor

All registered trials for this condition

Head and Neck Squamous Cell Carcinoma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.